What is the Theravance Biopharma Inc. stock price forecast?

Theravance Biopharma Inc. is currently trading at $16.69. View real-time AI analysis on Alpha Lenz.

What is Theravance Biopharma Inc. insider trading activity?

View the latest insider trading data for Theravance Biopharma Inc. on Alpha Lenz.

What is Theravance Biopharma Inc.'s P/E ratio?

Theravance Biopharma Inc.'s P/E ratio is 7.9.

Theravance Biopharma Inc.

NASDAQ · TBPH

$16.69+0.37(+2.27%)Pre-market

Ask about Theravance Biopharma Inc.'s future dividend policy...

Alpha Chat Insight

“Theravance Biopharma Inc. trades at a P/E of 7.9 (undervalued) with strong ROE of 44.8%. 3Y revenue CAGR of 27.9% highlights clear growth momentum.”

Ask for details →

Company Overview

Theravance Biopharma Inc. is a biopharmaceutical company engaged in the discovery, development, and commercialization of innovative medicines to address unmet clinical needs. Specializing in respiratory diseases, chronic obstructive pulmonary disease (COPD), and other serious illnesses, the company seeks to improve patient outcomes through advanced therapeutic solutions. Theravance Biopharma’s pipeline includes both inhalation products and small molecule drugs, reflecting its commitment to tackling complex medical challenges. Operating primarily within the healthcare and life sciences sectors, it collaborates with other pharmaceutical firms and research organizations to enhance its research capabilities and market reach. Headquartered in George Town, Cayman Islands, with additional operations in the United States, the company plays a significant role in the development of novel treatments that aim to transform patient care standards globally.

CEOMr. Rick E. Winningham M.B.A.

Websitehttps://www.theravance.com

SectorHealthcare

IndustryBiotechnology

Employees97

Company Statistics

FY 2025

Profile

$839.79MMarket Cap

$107.46MRevenue

0.00Shares Out

97Employees

Margins

N/AGross

55.26%EBITDA

-3.35%Operating

120.27%Pre-Tax

98.54%Net

Valuation

7.93P/E

2.83P/B

7.81EV/Sales

12.04EV/EBITDA

3.52P/FCF

Growth (CAGR)

27.91%Rev 3Yr

8.38%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

-50.48%Net Inc 3Yr

N/ANet Inc 5Yr

Returns

25.22%ROA

44.85%ROE

31.37%ROIC

Financial Health

$167.81MCash & Cash Equivalents

$21.04MNet Debt

63.64%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Theravance Biopharma Inc. trades at a P/E of 7.9 (undervalued) with strong ROE of 44.8%. 3Y revenue CAGR of 27.9% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

Theravance Biopharma Inc. (ticker: TBPH) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 97 employees. Market cap is $840M.

The current price is $16.69 with a P/E ratio of 7.93x and P/B of 2.83x.

ROE is 44.85% and operating margin is -3.35%. Annual revenue is $107M.